Mark of success
The advances we’ve seen in the discovery and use of genetic biomarkers in recent years have been remarkable. Look at the recent revolution in home DNA testing kits – now a burgeoning new industry expected to be worth £261m by 2022.
For the healthcare sector, the sky is the limit in terms of the potential this holds. Labs will soon offer direct-to-consumer testing for multi-analyte biomarker panels from a single drop of blood. Acquired in the home and sent through the post, this will enable personalised, precision medicine at a level that would have been unthinkable a few short years ago.
Women in pharma: Maria Belvisi
AstraZeneca’s vice president and head, IMED Respiratory on the importance of a supportive network and the challenges of a work-life balance
How did you get where you are today?
My career path started by going to a state-run school in Liverpool where there were very few girls that selected to study science subjects at A level. This may be because it was not actively pushed as a career option. Thankfully we live in a different world now but being successful as a woman in science still remains somewhat of a challenge.
